AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20542784 — intervention group
Group type: EXPERIMENTAL
Intervention: MAR-tyn stent (titanium-nitride coated)
Number of subjects: 160
Study 20542784 — intervention group
Group type: COMPARATOR
Intervention: Vision stent (control group)
Number of subjects: 160
Study 18838009 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month CHOICE program
Number of subjects: 0
Study 18838009 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-month CHOICE program (CHOICE-plus)
Number of subjects: 0
Study 18838009 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (control group)
Number of subjects: 0
Study 16206354 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral daily ibandronate
Number of subjects: 0
Study 16206354 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent ibandronate (interval between doses > 2 mo)
Number of subjects: 0
Study 16206354 — intervention group
Group type: COMPARATOR
Intervention: Calcium and vitamin D supplementation (placebo)
Number of subjects: 0
Study 12161547 — intervention group
Group type: EXPERIMENTAL
Intervention: HLP-meal (800-kcal, containing 53% lipids, 43% proteins, 4% carbohydrates)
Number of subjects: 30
Study 12161547 — intervention group
Group type: EXPERIMENTAL
Intervention: HCHO-meal (800-kcal, containing 89% carbohydrates, 11% proteins, 0% lipids)
Number of subjects: 30
Study 12161547 — intervention group
Group type: EXPERIMENTAL
Intervention: HLP-meal and HCHO-meal
Number of subjects: 30
Study 12161547 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups together after adjusting for body mass index
Number of subjects: 30
Study 12161547 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in ACTH and cortisol
Number of subjects: 30
Study 10712711 — intervention group
Group type: COMPARATOR
Intervention: 3% halothane in oxygen (Group H)
Number of subjects: 64
Study 10712711 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% isoflurane in oxygen (Group I)
Number of subjects: 64
Study 7734597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education program volunteers
Number of subjects: 487
Study 7734597 — intervention group
Group type: COMPARATOR
Intervention: Population sample
Number of subjects: 487
Study 1645664 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐Sestamibi
Number of subjects: 66
Study 7011112 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg reproterol
Number of subjects: 0
Study 7011112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30544284 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical diagnosis including small polyps (6-9 mm)
Number of subjects: 3144
Study 30544284 — intervention group
Group type: COMPARATOR
Intervention: Optical diagnosis excluding small polyps
Number of subjects: 3144
Study 28662897 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 247
Study 28662897 — intervention group
Group type: EXPERIMENTAL
Intervention: Reductions in psychological distress
Number of subjects: 247
Study 25491498 — intervention group
Group type: EXPERIMENTAL
Intervention: High-vegetable (HV) diet
Number of subjects: 88
Study 25491498 — intervention group
Group type: COMPARATOR
Intervention: High-protein (HP) diet
Number of subjects: 88
Study 24476473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa-enriched dark chocolate (DC)
Number of subjects: 16
Study 24476473 — intervention group
Group type: COMPARATOR
Intervention: Cocoa-depleted control (CON)
Number of subjects: 16
Study 23015569 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) treatment
Number of subjects: 53
Study 23015569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 20011855 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural block with 10 to 15 mL of 0.5% ropivacaine
Number of subjects: 41
Study 20011855 — intervention group
Group type: COMPARATOR
Intervention: Lumbar plexus block with 0.4 mL.kg(‐1) of 0.5% ropivacaine
Number of subjects: 41
Study 20011855 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural block
Number of subjects: 41
Study 20011855 — intervention group
Group type: COMPARATOR
Intervention: Lumbar plexus block
Number of subjects: 41
Study 17309918 — intervention group
Group type: EXPERIMENTAL
Intervention: HIF-1alpha (Ad2/HIF-1alpha/VP16) at doses of 1x10(8) to 2x10(11) viral particles
Number of subjects: 34
Study 17309918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 17309918 — intervention group
Group type: EXPERIMENTAL
Intervention: HIF-1alpha (Ad2/HIF-1alpha/VP16)
Number of subjects: 34
Study 15249351 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus (DM)
Number of subjects: 13105
Study 11731907 — intervention group
Group type: EXPERIMENTAL
Intervention: Valeriana edulis standardized hydroalcoholic extract (450 mg)
Number of subjects: 20
Study 11731907 — intervention group
Group type: COMPARATOR
Intervention: Valeriana officinalis extract (450 mg)
Number of subjects: 20
Study 9506488 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (5 mg/kg)
Number of subjects: 86
Study 9506488 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg/kg)
Number of subjects: 86
Study 9506488 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (5 microg/kg)
Number of subjects: 86
Study 9506488 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 86
Study 7512838 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (200 microgram/m2) starting daily from 2 days before induction therapy until neutrophils recovered to above 1,500/microL or until 35 days after therapy
Number of subjects: 58
Study 7512838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 7512838 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 58
Study 2855220 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 6
Study 2855220 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 6
Study 31621884 — intervention group
Group type: EXPERIMENTAL
Intervention: VA‐CRAFT website
Number of subjects: 41
Study 31621884 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 41
Study 30889155 — intervention group
Group type: EXPERIMENTAL
Intervention: Fisionerv® gel, 3 times/day added to physiotherapy (40 minutes daily session)
Number of subjects: 58
Study 30889155 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel (placebo, 3 times/day) added to physiotherapy (40 minutes daily session)
Number of subjects: 58
Study 30889155 — intervention group
Group type: EXPERIMENTAL
Intervention: Fisionerv® gel
Number of subjects: 58
Study 28758882 — intervention group
Group type: EXPERIMENTAL
Intervention: Patriarchal gender attitudes in boys
Number of subjects: 1752
Study 28758882 — intervention group
Group type: EXPERIMENTAL
Intervention: Patriarchal gender attitudes in girls
Number of subjects: 1752
Study 25814054 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus the 4-week yoga intervention (2x/week; 75 min/session) using the YOCAS©® program
Number of subjects: 167
Study 25814054 — intervention group
Group type: COMPARATOR
Intervention: Standard care monitoring
Number of subjects: 167
Study 23297841 — intervention group
Group type: EXPERIMENTAL
Intervention: VEN‐XR (up to 375 mg)
Number of subjects: 103
Study 23297841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 21783417 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day) until disease progression or unacceptable toxic effects
Number of subjects: 165
Study 21783417 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus carboplatin (up to four cycles)
Number of subjects: 165
Study 21783417 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (gemcitabine plus carboplatin)
Number of subjects: 165
Study 21783417 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 165
Study 21783417 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 165
Study 19703282 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical decompression (before 24 hours)
Number of subjects: 328
Study 19703282 — intervention group
Group type: COMPARATOR
Intervention: Late surgical decompression (24-72 hours)
Number of subjects: 328
Study 17087700 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin use
Number of subjects: 3072
Study 17087700 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual vitamin or mineral supplement
Number of subjects: 3072
Study 17087700 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonvitamin/nonmineral dietary supplement (NVNMDS)
Number of subjects: 3072
Study 15234411 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test in patients with IDCM
Number of subjects: 43
Study 15234411 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 43
Study 15234411 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with IDCM
Number of subjects: 43
Study 10932022 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic removal of third molars
Number of subjects: 200
Study 10932022 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 200
Study 10932022 — intervention group
Group type: COMPARATOR
Intervention: Retention of third molars
Number of subjects: 200
Study 9090346 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 33
Study 9090346 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 33
Study 8385180 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercise programme (three 30-min sessions a week of cycling at 60-70% of maximum workload)
Number of subjects: 75
Study 8385180 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol restriction (low-alcohol beer)
Number of subjects: 75
Study 8385180 — intervention group
Group type: COMPARATOR
Intervention: Control light-exercise programme
Number of subjects: 75
Study 3891456 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Number of subjects: 434
Study 3891456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 434
Study 31266506 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunchbox intervention
Number of subjects: 1915
Study 28968342 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM) training (N = 23)
Number of subjects: 66
Study 28968342 — intervention group
Group type: COMPARATOR
Intervention: Placebo training (N = 22)
Number of subjects: 66
Study 28968342 — intervention group
Group type: COMPARATOR
Intervention: No training (waitlist; N = 21)
Number of subjects: 66
Study 25295921 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrodesis of the first metatarsophalangeal joint
Number of subjects: 26
Study 25295921 — intervention group
Group type: COMPARATOR
Intervention: Resection of the first metatarsophalangeal joint
Number of subjects: 26
Study 23554177 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcissism
Number of subjects: 0
Study 23554177 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical attractiveness and social boldness
Number of subjects: 0
Study 21824186 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose
Number of subjects: 6025
Study 21824186 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA(1c)
Number of subjects: 6025
Study 19821105 — intervention group
Group type: EXPERIMENTAL
Intervention: rabdosia rubescens drop pill (960 mg) and 4 tablets of simulation agent, administered three times a day for 5 days
Number of subjects: 136
Study 19821105 — intervention group
Group type: COMPARATOR
Intervention: rabdosia rubescens tablet (1000 mg) and 24 drop pills of simulation agent, administered three times a day for 5 days
Number of subjects: 136
Study 17760546 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel in a silica base for 2 minutes (G1)
Number of subjects: 80
Study 17760546 — intervention group
Group type: COMPARATOR
Intervention: Neutral EDTA conditioning agent for 2 minutes followed by placebo gel (G2)
Number of subjects: 80
Study 17760546 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% CHX digluconate gel in a silica base (G3)
Number of subjects: 80
Study 17760546 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral EDTA conditioning agent for 2 minutes followed by CHX gel (G4)
Number of subjects: 80
Study 14998597 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management programs
Number of subjects: 0
Study 11172955 — intervention group
Group type: EXPERIMENTAL
Intervention: Central lymphatic irradiation (CLI)
Number of subjects: 33
Study 11172955 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment PCR results
Number of subjects: 33
Study 11172955 — intervention group
Group type: EXPERIMENTAL
Intervention: International Prognostic Index (IPI)
Number of subjects: 33
Study 8187474 — intervention group
Group type: COMPARATOR
Intervention: No eating disorder at follow-up
Number of subjects: 59
Study 8187474 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe eating disorder (anorexia or bulimia nervosa)
Number of subjects: 59
Study 8187474 — intervention group
Group type: EXPERIMENTAL
Intervention: NOS eating disorder diagnosis at follow-up
Number of subjects: 59
Study 8187474 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of eating disorder symptom severity
Number of subjects: 59
Study 8187474 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of psychopathology on the MMPI
Number of subjects: 59
Study 2842405 — intervention group
Group type: EXPERIMENTAL
Intervention: WC3 rotavirus vaccine
Number of subjects: 104
Study 2842405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 31151390 — intervention group
Group type: COMPARATOR
Intervention: Arm 1 (Usual Care): 10% cash back, no weekly text, standard monthly text
Number of subjects: 2841
Study 31151390 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm 2: 10% cash back, generic weekly text, standard monthly text
Number of subjects: 2841
Study 28526026 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth information leaflets (THLs)
Number of subjects: 14
Study 24499051 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 23
Study 24499051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 23558760 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine
Number of subjects: 40
Study 23558760 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl
Number of subjects: 40
Study 20839291 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg
Number of subjects: 429
Study 20839291 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 40 mg
Number of subjects: 429
Study 20839291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 18809166 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-page informational handout
Number of subjects: 387
Study 16844713 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (STN DBS)
Number of subjects: 18
Study 16844713 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous levodopa infusion
Number of subjects: 18
Study 12959805 — intervention group
Group type: EXPERIMENTAL
Intervention: Way-finding intervention using a location map and behavioral training technique over one month
Number of subjects: 32
Study 12959805 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study 12959805 — intervention group
Group type: EXPERIMENTAL
Intervention: Way-finding intervention
Number of subjects: 32
Study 10752492 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg at bedtime
Number of subjects: 21
Study 10752492 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 21
Study 9203718 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral poliovirus vaccine (OPV) during NID
Number of subjects: 1288
Study 9203718 — intervention group
Group type: COMPARATOR
Intervention: Unimmunized or partially immunized children
Number of subjects: 1288
Study 9203718 — intervention group
Group type: COMPARATOR
Intervention: Children 0-11 months of age
Number of subjects: 1288
Study 9203718 — intervention group
Group type: EXPERIMENTAL
Intervention: Television and radio as mass media
Number of subjects: 1288
Study 9203718 — intervention group
Group type: COMPARATOR
Intervention: Other mass media
Number of subjects: 1288
Study 8381091 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo prednisolone treatment
Number of subjects: 0
Study 8381091 — intervention group
Group type: COMPARATOR
Intervention: Submaximal concentrations of calcium ionophore A23187 and phorbol myristate acetate stimulation
Number of subjects: 0
Study 3079540 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 X 10(6) U IFN‐beta ser i.v. daily for 10 days
Number of subjects: 2
Study 3079540 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 X 10(6) U IFN‐beta ser i.v. daily for 10 days
Number of subjects: 2
Study 30489526 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous aponeurotomy with lipofilling (PALF)
Number of subjects: 52
Study 30489526 — intervention group
Group type: COMPARATOR
Intervention: Limited fasciectomy
Number of subjects: 52
Study 27686547 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 104
Study 27686547 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral Approach (PLA)
Number of subjects: 104
Study 26300329 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 97
Study 26300329 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Cognitive Therapy (NCT)
Number of subjects: 97
Study 26300329 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CBT and NCT combined)
Number of subjects: 97
Study 20674902 — intervention group
Group type: EXPERIMENTAL
Intervention: Swim-up
Number of subjects: 53
Study 20674902 — intervention group
Group type: COMPARATOR
Intervention: Density gradient centrifugation
Number of subjects: 53
Study 18498589 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of dental implants
Number of subjects: 10
Study 18498589 — intervention group
Group type: COMPARATOR
Intervention: Early loading of dental implants
Number of subjects: 10
Study 18498589 — intervention group
Group type: COMPARATOR
Intervention: Moderately rough surface implants
Number of subjects: 10
Study 18498589 — intervention group
Group type: COMPARATOR
Intervention: Novel one-piece implant design
Number of subjects: 10
Study 16536665 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (mean postdrinking blood alcohol concentration = 0.056%)
Number of subjects: 60
Study 16536665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16536665 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 60
Study 16536665 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol and VLT play
Number of subjects: 60
Study 12549992 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (not specified dosage or duration)
Number of subjects: 0
Study 12549992 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (specific dosage and duration not mentioned)
Number of subjects: 0
Study 12549992 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions (smoking cessation, heart healthy diet, weight control, physical activity)
Number of subjects: 0
Study 12549992 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use for control of elevated LDL cholesterol levels
Number of subjects: 0
Study 12549992 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic blood pressure control
Number of subjects: 0
Study 11049204 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg/d selenite Se
Number of subjects: 30
Study 11049204 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg/d Se-yeast
Number of subjects: 30
Study 11049204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8816210 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone therapy (0.5 mg/kg per day for 5 days)
Number of subjects: 26
Study 8112809 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg zinc/p.o./day as 200 mg 'zinc sulphate tablets
Number of subjects: 162
Study 8112809 — intervention group
Group type: COMPARATOR
Intervention: Control group (no zinc administration)
Number of subjects: 162
Study 3755875 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 0
Study 3755875 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 31997526 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 29
Study 31997526 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 29
Study 30334692 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-445-tezacaftor-ivacaftor
Number of subjects: 2
Study 26899786 — intervention group
Group type: EXPERIMENTAL
Intervention: rtfMRI‐NF training for anterior insula regulation
Number of subjects: 0
Study 26899786 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study 25346818 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal injection
Number of subjects: 30
Study 25346818 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal injection
Number of subjects: 30
Study 21692827 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg kg⁻¹ infusions at weeks 0, 2, 6, 12 and 18
Number of subjects: 26
Study 21692827 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg kg⁻¹ infusions
Number of subjects: 26
Study 20601389 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based regimen
Number of subjects: 9190
Study 20601389 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol-based regimen
Number of subjects: 9190
Study 20601389 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistence or development of HR ≥ 84 bpm
Number of subjects: 9190
Study 20601389 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher in-treatment HR in time-varying multivariable Cox models
Number of subjects: 9190
Study 18719654 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (WL; > or =5 lb loss)
Number of subjects: 248
Study 18719654 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight stable (WS; <+/‐5 lb change)
Number of subjects: 248